This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Hemostatic Matrix in Endoscopic Sinus Surgery

This study has been completed.
Information provided by:
Ethicon, Inc. Identifier:
First received: October 19, 2005
Last updated: July 11, 2006
Last verified: July 2006
Evaluating clinical performance of Hemostatic Matrix with bovine thrombin in achieving hemostasis in patients undergoing endoscopic sinus surgery.

Condition Intervention Phase
Sinusitis Device: Hemostatic matrix Device: bovine thrombin Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Educational/Counseling/Training
Official Title: A Prospective, Multicenter Study to Evaluate Hemostatic Matrix With Bovine Thrombin in Achieving Hemostasis in Patients Undergoing Endoscopic Sinus Surgery

Resource links provided by NLM:

Further study details as provided by Ethicon, Inc.:

Primary Outcome Measures:
  • Success in achieving hemostasis after product application

Secondary Outcome Measures:
  • Post operative healing
  • Patient Satisfaction
  • Time to hemostasis

Estimated Enrollment: 30
Study Start Date: October 2005
Estimated Study Completion Date: February 2006

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Patients who are 18 years or older.
  • Patients undergoing elective primary or re-do endoscopic sinus surgery for chronic sinusitis with bleeding surface requiring an adjunct to achieve hemostasis.
  • Patients must be willing and capable of cooperating to the extent and degree required by the protocol and sign the IRB approved Informed Consent Form prior to any participation in the study.

Exclusion Criteria:

  • Patients with bleeding diathesis, pathologic coagulopathy, systemic disorders, inflammatory conditions (other than chronic sinusitis or nasal polyposis) or autoimmune, immunodeficiency diseases or any other disorder that may interfere with hemostasis.
  • Patients with severe (brisk or forceful) bleeding site(s).
  • Patients undergoing urgent or emergency endoscopic sinus surgery.
  • Patients with bronchial asthma who have aspirin intolerance.
  • Patients with diffuse polyposis that would require chronic oral steroids or patients on chemotherapeutic agents that might delay healing (short term pulse steroid therapy and topical steroids are acceptable).
  • Patients who have used anticoagulant, antiplatelet or nonsteroidal anti-inflammatory analgesic (NSAID) within 7 days prior to surgery.
  • Patients who are morbidly obese (Body Mass Index > 35).
  • Patients with acute local infection at the operative side.
  • Patients who are current alcohol and/or drug abusers.
  • Patients with neoplasm, craniofacial abnormalities (e.g. cleft palate), or sleep apnea using nasal CPAP, or patients that may require a Lothrop procedure.
  • Female patients who are pregnant or nursing.
  • Patients who have uncontrolled diabetes mellitus (blood glucose levels >400 mg/dl) as determined by the Investigator based on medical history.
  • Patients who have participated in another investigational drug or device research within 30 days of enrollment.
  • Patients with known antibodies to bovine thrombin preparations, sensitivities or religious prohibitions to porcine gelatin or bovine components.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00242437

United States, New Jersey
The Summit Medical GroupDepartment of Otolaryngology
Summit, New Jersey, United States, 07901
United States, South Carolina
The Medical University of South Carolina Department of Otolaryngology
Charleston, South Carolina, United States, 29425-0550
United States, Tennessee
University of Tennessee Department of Otolaryngology
Memphis, Tennessee, United States, 38163
Sponsors and Collaborators
Ethicon, Inc.
Study Director: James Hart, MD Ethicon, Inc.
  More Information Identifier: NCT00242437     History of Changes
Other Study ID Numbers: 400-05-002
Study First Received: October 19, 2005
Last Updated: July 11, 2006

Additional relevant MeSH terms:
Paranasal Sinus Diseases
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Coagulants processed this record on September 21, 2017